Sydney - Tuesday - December 16: (RWE Aust Business News)...

Sydney - Tuesday - December 16: (RWE Aust Business News) -
Alchemia (ASX:ACL) has achieved a significant milestone towards the
commercialisation of its lead product, generic fondaparinux.
As a consequence Alchemia will receive payments from its
manufacturing and marketing partner Dr Reddy's totalling $2.4 million.
The trigger for the payment, which is subject to confidentiality
under the terms of Alchemia's commercialisation agreements, signals
important progress toward the filing of the fondaparinux ANDA with the US
Federal Drug Administration.
Meanwhle, US sales of Arixtra in the 12 months to September 2008
were $US172m up 67pc on the corresponding period last year.
The receipt of these payments further improves Alchemia's cash
position, providing in excess of two years operational funding at current
expenditure levels.